Whenever a pharmaceutical company tests a new migraine prevention drug, nearly 1 in 20 subjects will drop out because they can't stand the drug's side effects. They'd rather deal with the headaches than keep receiving treatment. But those suffering patients might be surprised to learn that the drug they've quit is only a sugar pill: the 5 percent dropout rate is from the placebo side.